Synthetic cannabimimetic agents metabolized by carboxylesterases

Drug Testing and Analysis

Volumn 7, Issue 7, 2015, Pages 565-576

  Thomsen, Ragnar ^a   Nielsen, Line M ^a   Holm, Niels B ^a   Rasmussen, Henrik Berg ^b   Linnet, Kristian ^a   Bjerre, Ditte ^b   Madsen, Majbritt Busk ^b   Ferrero, Laura ^b   Jürgens, Gesche ^c   Dalhoff, Kim ^c   Stage, Claus ^c   Stefansson, Hreinn ^c   Hankemeier, Thomas ^d   Kaddurah Daouk, Rima ^e   Brunak, Søren ^f   Taboureau, Olivier ^f   Nzabonimpa, Grace Shema ^f   Houmann, Tine ^g   Jeppesen, Pia ^g   Kaalund Jørgesen, Kristine ^g   Hansen, Peter Riis ^b   Kristensen, Karl Emil ^b   Pagsberg, Anne Katrine ^g   Plessen, Kerstin ^g   Hansen, Poul Erik ^h   Werge, Thomas ^b   Dyrborg, Jørgen ^g   Lauritzen, Maj Britt ^g   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c DECODE GENETICS   (Iceland)

^d LEIDEN UNIVERSITY   (Netherlands)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^g Mental Health Services in the Capital Region of Denmark   (Denmark)

^h ROSKILDE UNIVERSITY   (Denmark)

Author keywords

Carboxylesterase; Human liver microsomes; Metabolism; Synthetic cannabinoids

Indexed keywords

AMIDES; ENZYMATIC HYDROLYSIS; ENZYME INHIBITION; ESTERS; METABOLISM; METABOLITES;

AMIDE HYDROLYSIS; CANNABIMIMETIC; CANNABINOID RECEPTORS; CARBOXAMIDES; CARBOXYLESTERASES; HUMAN LIVER MICROSOMES; INDAZOLE; LARGE GROUPS; METABOLIC PATHWAYS; SYNTHETIC CANNABINOID;

HYDROXYLATION;

5F PB 22; ACETYLCHOLINESTERASE; BB 22; CANNABINOID DERIVATIVE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CHOLINESTERASE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1-PENTYL 1H INDAZOLE 3 CARBOXAMIDE; PB 22; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; CANNABINOID;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER METABOLISM; LIVER MICROSOME; METABOLITE; MICROSOME; PRIORITY JOURNAL; PULMONARY MICROSOME; XENOBIOTIC METABOLISM; FEMALE; MALE; METABOLISM; SYNTHESIS;

BIOMIMETIC MATERIALS; CANNABINOIDS; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; MALE; MICROSOMES, LIVER;

EID: 84937718800     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1731     Document Type: Article

References (54)

1. Y. Gaoni, R. Mechoulam . Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646.
2. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, T.I. Bonner . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561.
3. S. Munro, K.L. Thomas, M. Abu-Shaar . Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61.
4. R. Sedefov, A. Gallegos, L. King, D. Lopez, V. Auwärter, B. Hughes, P. Griffiths . Understanding the 'Spice' phenomenon, EMCDDA, 2009.
5. N. Uchiyama, R. Kikura-Hanajiri, N. Kawahara, Y. Haishima, Y. Goda . Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. (Tokyo) 2009, 57, 439.
6. V. Auwärter, S. Dresen, W. Weinmann, M. Müller, M. Pütz, N. Ferreirós . "Spice" and other herbal blends: Harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 2009, 44, 832.
7. L. Fattore, W. Fratta . Beyond THC: The new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 2011, 5, 60.
8. Danish Ministry of Health. Nr. 778 Bekendtgørelse om ændring af bekendtgørelse om euforiserende stoffer. Available at: https://www.retsinformation.dk/Forms/R0710.aspx?id=142729 [29 July 2014].
9. Drug Enforcement Administration. Schedules of controlled substances: Temporary placement of four synthetic cannabinoids into Schedule I. Final order. Fed. Regist. 2014, 79, 7577.
10. N. Uchiyama, S. Matsuda, M. Kawamura, R. Kikura-Hanajiri, Y. Goda . Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-79. Forensic Toxicol. 2013, 31, 223.
11. G. Behonick, K.G. Shanks, D.J. Firchau, G. Mathur, C.F. Lynch, M. Nashelsky, D.J. Jaskierny, C. Meroueh . Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J. Anal. Toxicol. 2014, 38, 559.
12. N. Uchiyama, S. Matsuda, D. Wakana, R. Kikura-Hanajiri, Y. Goda . New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs i. Forensic Toxicol. 2013, 31, 93.
13. A.A. Monte, A.C. Bronstein, D.J. Cao, K.J. Heard, J.A. Hoppe, C.O. Hoyte, J.L. Iwanicki, E.J. Lavonas . An outbreak of exposure to a novel synthetic cannabinoid. New Engl. J. Med. 2014, 370, 389.
14. I. Buchler, M. Hayes, S. Hegde, S. Hockerman, S. Jones, S. Kortum, J. Rico, R. Tenbrink, K. Wu . Indazole derivatives as CB1 receptor modulators their preparation and use in the treatment of CB1-mediated diseases. Patent No. WO/2009/106982, 2009.
15. M.M. Aung, G. Griffin, J.W. Huffman, M. Wu, C. Keel, B. Yang, V.M. Showalter, M.E. Abood, B.R. Martin . Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend. 2000, 60, 133.
16. A. Wohlfarth, A.S. Gandhi, S. Pang, M. Zhu, K.B. Scheidweiler, M.A. Huestis . Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 1763.
17. T. Takayama, M. Suzuki, K. Todoroki, K. Inoue, J.Z. Min, R. Kikura-Hanajiri, Y. Goda, T. Toyo'oka . UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome. Biomed. Chromatogr. 2014, 28, 831.
18. T. Fukami, T. Yokoi . The emerging role of human esterases. Drug Metab. Pharmacokinet. 2012, 27, 466.
19. J. Massoulié, L. Pezzementi, S. Bon, E. Krejci, F.M. Vallette . Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 1993, 41, 31.
20. A. Tunek, E. Levin, L.A. Svensson . Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem. Pharmacol. 1988, 37, 3867.
21. C. Mattes, R. Bradley, E. Slaughter, S. Browne . Cocaine and butyrylcholinesterase (BChE): Determination of enzymatic parameters. Life Sci. 1996, 58, PL257.
22. T. Satoh, P. Taylor, W.F. Bosron, S.P. Sanghani, M. Hosokawa, B.N. La Du . Current progress on esterases: From molecular structure to function. Drug Metab. Dispos. 2002, 30, 488.
23. R. Thomsen, H.B. Rasmussen, K. Linnet . In vitro drug metabolism by human carboxylesterase 1: Focus on angiotensin-converting enzyme inhibitors. Drug Metab. Dispos. 2014, 42, 126.
24. Z. Sun, D.J. Murry, S.P. Sanghani, W.I. Davis, N.Y. Kedishvili, Q. Zou, T.D. Hurley, W.F. Bosron . Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J. Pharmacol. Exp. Ther. 2004, 310, 469.
25. D. Shi, J. Yang, D. Yang, E.L. LeCluyse, C. Black, L. You, F. Akhlaghi, B. Yan . Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 2006, 319, 1477.
26. E.T. Williams, J.E. Carlson, W.G. Lai, Y.N. Wong, T. Yoshimura, D.J. Critchley, M. Narurkar . Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab. Lett. 2011, 5, 280.
27. M. Tang, M. Mukundan, J. Yang, N. Charpentier, E.L. LeCluyse, C. Black, D. Yang, D. Shi, B. Yan . Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 2006, 319, 1467.
28. J. Zhang, J.C. Burnell, N. Dumaual, W.F. Bosron . Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J. Pharmacol. Exp. Ther. 1999, 290, 314.
29. S.C. Laizure, R.B. Parker, V.L. Herring, Z.-Y. Hu . Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab. Dispos. 2014, 42, 201.
30. R. Humerickhouse, K. Lohrbach, L. Li, W.F. Bosron, M.E. Dolan . Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 2000, 60, 1189.
31. E.T. Williams, K.O. Jones, G.D. Ponsler, S.M. Lowery, E.J. Perkins, S.A. Wrighton, K.J. Ruterbories, M. Kazui, N.A. Farid . The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab. Dispos. 2008, 36, 1227.
32. Y. Kobayashi, T. Fukami, M. Shimizu, M. Nakajima, T. Yokoi . Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab. Dispos. 2012, 40, 1080.
33. A. Nakajima, T. Fukami, Y. Kobayashi, A. Watanabe, M. Nakajima, T. Yokoi . Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: Rifampicin, rifabutin, and rifapentine. Biochem. Pharmacol. 2011, 82, 1747.
34. A. Watanabe, T. Fukami, S. Takahashi, Y. Kobayashi, N. Nakagawa, M. Nakajima, T. Yokoi . Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Drug Metab. Dispos. 2010, 38, 1532.
35. D.I. Draganov, J.F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, B.N. La Du . Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 2005, 46, 1239.
36. E.K. Tarkiainen, J.T. Backman, M. Neuvonen, P.J. Neuvonen, M. Schwab, M. Niemi . Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin. Pharmacol. Ther. 2012, 92, 68.
37. M.C. McGuire, C.P. Nogueira, C.F. Bartels, H. Lightstone, A. Hajra, A.F. Van der Spek, O. Lockridge, B.N. La Du . Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 953.
38. L.G. Costa, G. Giordano, T.B. Cole, J. Marsillach, C.E. Furlong . Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2013, 307, 115.
39. G.L. Ellman, K.D. Courtney, V. Andres, R.M. Feather-Stone . A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88.
40. L. Austin, W.K. Berry . Two selective inhibitors of cholinesterase. Biochem. J. 1953, 54, 695.
41. P. Eyer, F. Worek, D. Kiderlen, G. Sinko, A. Stuglin, V. Simeon-Rudolf, E. Reiner . Molar absorption coefficients for the reduced Ellman reagent: Reassessment. Anal. Biochem. 2003, 312, 224.
42. E.T. Williams, M.E. Ehsani, X. Wang, H. Wang, Y.-W. Qian, S.A. Wrighton, E.J. Perkins . Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases. J. Pharmacol. Toxicol. Methods 2008, 57, 138.
43. R.M. Wadkins, J.L. Hyatt, X. Wei, K.J.P. Yoon, M. Wierdl, C.C. Edwards, C.L. Morton, J.C. Obenauer, K. Damodaran, P. Beroza, M.K. Danks, P.M. Potter . Identification and characterization of novel benzil (diphenylethane-1, 2-dione) analogues as inhibitors of mammalian carboxylesterases. J. Med. Chem. 2005, 48, 2906.
44. S.K. Quinney, S.P. Sanghani, W.I. Davis, T.D. Hurley, Z. Sun, D.J. Murry, W.F. Bosron . Hydrolysis of capecitabine to 5J{cyrillic}-Deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. Pharmacology 2005, 313, 1011.
45. R.C. Sorenson, S.L. Primo-Parmo, C.L. Kuo, S. Adkins, O. Lockridge, B.N. La Du . Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 7187.
46. A. Watanabe, T. Fukami, M. Nakajima, M. Takamiya, Y. Aoki, T. Yokoi . Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab. Dispos. 2009, 37, 1513.
47. E.V. Pindel, N.Y. Kedishvili, T.L. Abraham, M.R. Brzezinski, J. Zhang, R.A. Dean, W.F. Bosron . Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem. 1997, 272, 14769.
48. D.J. Triggle, J.M. Mitchell, R. Filler . The pharmacology of physostigmine. CNS Drug Rev. 1998, 4, 87.
49. P.G. Wells, P.I. Mackenzie, J.R. Chowdhury, C. Guillemette, P.A. Gregory, Y. Ishii, A.J. Hansen, F.K. Kessler, P.M. Kim, N.R. Chowdhury, J.K. Ritter . Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 2004, 32, 281.
50. A. Negrusz, G. Cooper . Clarke's Analytical Forensic Toxicology. Pharmaceutical Press: London, 2013.
51. M.A. ElSohly, W. Gul, K.M. Elsohly, T.P. Murphy, V.L.M. Madgula, S.I. Khan . Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J. Anal. Toxicol. 2011, 35, 487.
52. A. Wohlfarth, S. Pang, M. Zhu, A.S. Gandhi, K.B. Scheidweiler, H. Liu, M.A. Huestis . First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin. Chem. 2013, 59, 1638.
53. A.S. Gandhi, M. Zhu, S. Pang, A. Wohlfarth, K.B. Scheidweiler, H. Liu, M.A. Huestis . First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013, 15, 1091.
54. N.B. Holm, A.J. Pedersen, P.W. Dalsgaard, K. Linnet . Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test. Anal. 2014. DOI: 10.1002/dta.1663